Liver Disease in Cystic Fibrosis: an Update

被引:28
作者
Parisi, Giuseppe Fabio [1 ]
Di Dio, Giovanna [1 ]
Franzonello, Chiara [1 ]
Gennaro, Alessia [1 ]
Rotolo, Novella [1 ]
Lionetti, Elena [1 ]
Leonardi, Salvatore [1 ]
机构
[1] Univ Catania, Dept Med & Pediat Sci, Bronchopneumol & Cyst Fibrosis Unit, Catania, Italy
关键词
Cystic Fibrosis; Liver Disease; Mutation; TRANSMEMBRANE CONDUCTANCE REGULATOR; HEPATIC STELLATE CELLS; HEPATOBILIARY DISEASE; RISK-FACTORS; CHILDREN; TRANSPLANTATION; MANIFESTATIONS; ULTRASOUND; MANAGEMENT; EXPRESSION;
D O I
10.5812/hepatmon.11215
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Context: Cystic fibrosis (CF) is the most widespread autosomal recessive genetic disorder that limits life expectation amongst the Caucasian population. As the median survival has increased related to early multidisciplinary intervention, other manifestations of CF have emergedespecially for the broad spectrum of hepatobiliary involvement. The present study reviews the existing literature on liver disease in cystic fibrosis and describes the key issues for an adequate clinical evaluation and management of patients, with a focus on the pathogenetic, clinical and diagnostic-therapeutic aspects of liver disease in CF. Evidence Acquisition: A literature search of electronic databases was undertaken for relevant studies published from 1990 about liver disease in cystic fibrosis. The databases searched were: EMBASE, PubMed and Cochrane Library. Results: CF is due to mutations in the gene on chromosome 7 that encodes an amino acidic polypeptide named CFTR (cystic fibrosis transmembrane regulator). The hepatic manifestations include particular changes referring to the basic CFTR defect, iatrogenic lesions or consequences of the multisystem disease. Even though hepatobiliary disease is the most common non-pulmonary cause ofmortalityin CF (the third after pulmonary disease and transplant complications), only about the 33%ofCF patients presents clinically significant hepatobiliary disease. Conclusions: Liver disease will have a growing impact on survival and quality of life of cystic fibrosis patients because a longer life expectancy and for this it is important its early recognition and a correct clinical management aimed atdelaying the onset of complications. This review could represent an opportunity to encourage researchers to better investigate genotype-phenotype correlation associated with the development of cystic fibrosis liver disease, especially for non-CFTR genetic polymorphisms, and detect predisposed individuals. Therapeutic trials are needed to find strategies of fibrosis prevention and to avoid its progression prior to development its related complications.
引用
收藏
页数:8
相关论文
共 75 条
  • [51] Gastrointestinal tract in liver disease: which organ is sick?
    Norman, Kristina
    Pirlich, Matthias
    [J]. CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2008, 11 (05) : 613 - 619
  • [52] Hepatocellular carcinoma complicating cystic fibrosis related liver disease
    O'Donnell, D. H.
    Ryan, R.
    Hayes, B.
    Fennelly, D.
    Gibney, R. G.
    [J]. JOURNAL OF CYSTIC FIBROSIS, 2009, 8 (04) : 288 - 290
  • [53] Liver disease in children with cystic fibrosis: US-biochemical comparison in 195 patients
    Patriquin, H
    Lenaerts, C
    Smith, L
    Perreault, G
    Grignon, A
    Filiatrault, D
    Boisvert, J
    Roy, CC
    Rasquin-Weber, A
    [J]. RADIOLOGY, 1999, 211 (01) : 229 - 232
  • [54] Transcriptional Basis for Hepatic Fibrosis in Cystic Fibrosis-associated Liver Disease
    Pereira, Tamara N.
    Lewindon, Peter J.
    Greer, Ristan M.
    Hoskins, Anita C.
    Williamson, Richard M.
    Shepherd, Ross W.
    Ramm, Grant A.
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2012, 54 (03) : 328 - 335
  • [55] Serum markers of hepatic fibrogenesis in cystic fibrosis liver disease
    Pereira, TN
    Lewindon, PJ
    Smith, JL
    Murphy, TL
    Lincoln, DJ
    Shepherd, RW
    Ramm, GA
    [J]. JOURNAL OF HEPATOLOGY, 2004, 41 (04) : 576 - 583
  • [56] Can the histologic changes of cystic fibrosis-associated hepatobiliary disease be predicted by clinical criteria?
    Potter, CJ
    Fishbein, M
    Hammond, S
    McCoy, K
    Qualman, S
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 1997, 25 (01) : 32 - 36
  • [57] Toll-like Receptor 4 and Hepatic Fibrogenesis
    Pradere, Jean-Philippe
    Troeger, Juliane S.
    Dapito, Dianne H.
    Mencin, Ali A.
    Schwabe, Robert F.
    [J]. SEMINARS IN LIVER DISEASE, 2010, 30 (03) : 232 - 244
  • [58] Serum Proteome Profiling Identifies Novel and Powerful Markers of Cystic Fibrosis Liver Disease
    Rath, Timo
    Hage, Lisa
    Kuegler, Marion
    Menendez, Katrin Menendez
    Zachoval, Reinhart
    Naehrlich, Lutz
    Schulz, Richard
    Roderfeld, Martin
    Roeb, Elke
    [J]. PLOS ONE, 2013, 8 (03):
  • [59] Mechanisms of disease: Cystic fibrosis
    Rowe, SM
    Miller, S
    Sorscher, EJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (19) : 1992 - 2001
  • [60] Outcome in Cystic Fibrosis Liver Disease
    Rowland, Marion
    Gallagher, Charles G.
    O'Laoide, Risteard
    Canny, Gerard
    Broderick, Annemarie
    Hayes, Roisin
    Greally, Peter
    Slattery, Dubhfeassa
    Daly, Leslie
    Durie, Peter
    Bourke, Billy
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 (01) : 104 - 109